Pages

Showing posts with label Bone Marrow Failure Syndromes. Show all posts
Showing posts with label Bone Marrow Failure Syndromes. Show all posts

Wednesday 20 November 2019

Bone Marrow Failure Syndromes – Ayurvedic Herbal Treatment

Bone Marrow Failure Syndromes (BMFS) are a group of medical disorders in which there is a paucity of RBCs, WBCs and Platelets in the blood either singly or all together (pancytopenia). These conditions may be either hereditary or acquired. Syndromes that result in pancytopenia include the following: Fanconi Anemia and Dyskeratosis Congenita. Syndromes usually limited to single hematopoietic lineage include the following: Severe Congenital Neutropenia (SCN), including Kostmann syndrome, Diamond-Blackfan Anemia, Shwachman-Diamond Syndrome, Congenital Amegakaryocytic Thrombocytopenia (CAMT), and Thrombocytopenia Absent Radii (TAR) syndrome.

BMFS are usually caused by dysfunctional stem cell production, defective growth factors, a dysfunctional environment, defective nutrition, accelerated cell death, and in the case of acquired aplastic anemia, immune-mediated abnormalities. Severe anemia can cause fatigue and cardiac failure; low leukocyte count can increase susceptibility to infections; and low platelet count can cause spontaneous bleeding.  Several inherited BMFS are associated with a high risk of leukemia and solid tumours.

Diamond-Blackfan anemia is a pure red cell aplasia, usually diagnosed in the first year. Physical abnormalities may or may not be present. Most patients improve with corticosteroid treatment, failing which, red cell transfusions with iron chelation, and lastly, stem cell transplant may be tried. ShwachmanDiamond syndrome (SDS), or Shwachman–Bodian–Diamond syndrome, is a rare congenital disorder characterized by exocrine pancreatic insufficiency, bone marrow dysfunction, skeletal abnormalities and short stature.Treatment of SDS includes pancreatic enzyme replacement, intravenous antibiotics, transfusions of RBCs, platelets and granulocyte colony stimulating factor (G-CSF), and orthopedic surgery as required.

TAR is diagnosed exclusively in the neonatal period. Treatment is with platelet transfusions. Surgery and stem cell transplantation are used as required. CAMT presents with isolated thrombocytopenia in infancy and develops into pancytopenia in later childhood. It has tendency to transform into Myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The primary treatment is bone marrow transplantation. SCN is defined as early onset severe neutropenia, with most patients developing MDS or AML. Patients often improve when treated with G-CSF; however, annual bone marrow assessment is mandatory to check for serious side effects.

            Fanconi anemia is one of the most common inherited BMFSs, with nearly 75% patients exhibiting some physical abnormalities. Standard treatment consists of need based transfusion with RBC and platelets, antibiotics, HLA-matched donor stem cell transplant, and treatment with androgens. Patients in the long run may develop leukemia, MDF and solid tumours. Dyskeratosis congenita is a rare and progressive congenital disorder with characteristic features of skin hyperpigmentation, nail dystrophy and oral leukoplakia. Treatment is with androgens, with the addition of erythropoietin, and G-CSF. The overall results of bone marrow transplant are poor. About 15 % of patients are likely to develop cancer.

            Acquired aplastic anemia is a BMFS which can be life threatening if left untreated. Exposure to chemicals and drugs, pregnancy, immune dysfunction, and a genetic predisposition are believed to cause this condition. It can lead to other disorders like paroxysmal nocturnal hemoglobinuria (PNH), MDS, and AML. Treatment options include immune suppressive therapy with antithymocyte globulin (ATG) and cyclosporine (CsA) or high–dose cyclophosphamide. With the availability of a suitable donor, hematopoietic stem-cell transplantation offers an opportunity for cure.

            Almost all BMFS have a serious prognosis, with a magnified long term risk for malignancies. Specific treatments are available which may positively impact the course of the disease; however, most are associated with serious long term side effects. In this scenario, Ayurvedic herbal medicines offer an alternative treatment option which can be safely used for long periods both in children as well as adults and helps keep the blood counts stable at acceptable levels.

            The therapeutic action of Ayurvedic herbal medicines in BMFS is at multiple levels. Some medicines stimulate the bone marrow and help accelerate the proliferation and differentiation of the hematopoietic system. Some medicines help normalize specific and general tissue metabolism as well as metabolite nutrition channels. Herbal medicines and herbomineral compounds help provide an optimum environment which gradually helps dilute the deleterious effect of dysfunctional genes and slows down the death rate of healthy cells. Ayurvedic herbal medicines also help optimize a faulty immune system so that it gradually starts working in favor of the body systems and not against them.

            Depending upon the type of BMFS and the presenting severity, different permutations and combinations of Ayurvedic herbal medicines may be required for effective treatment and lasting results. Modifications in the medical protocol and dosage may also be required as per patient feedback and observed clinical effects.  An average of six to twelve months of regular treatment may be required to stabilize the blood picture in a typical adult patient; further treatment decisions need to be taken on an individual case-to-case basis.

            Ayurvedic treatment can thus help stabilize and maintain patients with BMFS, both in adults as well as in children. In addition to a very low risk profile for side effects, Ayurvedic herbal treatment can cost just a fraction of the cost of modern treatment. Because of the serious nature and poor long term prognosis of BMFS, with the potential for long term complications and high probability of cancer, all patients taking Ayurvedic herbal treatment should be under the concurrent regular supervision  of several health professionals, including a hematologist, and a general physician.

The writer, Dr A A Mundewadi, is available as an Ayurvedic consultant at https://www.mundewadiayurvedicclinic.com and http://www.ayurvedaphysician.com